– FINLAND, Turku – Faron Pharmaceuticals Oy (LON: FARN / First North: FARON) announced the election of Non-Executive Director Tuomo Pätsi as Chair of its Board of Directors following the AGM on April 5, 2024.
Frank Armstrong and Erik Ostrowsi did not stand for re-election.
About Faron Pharmaceuticals Oy
Faron is a global, clinical-stage biopharmaceutical company, focused on tackling cancers via novel immunotherapies. Its mission is to bring the promise of immunotherapy to a broader population by uncovering novel ways to control and harness the power of the immune system. The Company’s lead asset is bexmarilimab, a novel anti-Clever-1 humanized antibody, potentially removing cancer immunosuppression by targeting myeloid cell function. Bexmarilimab is being investigated in Phase I/II clinical trials as a potential therapy for patients with hematological cancers in combination with other standard treatment treatments and as a monotherapy in last-line solid cancers.
SOURCE: https://www.faron.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
